CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.
Zacks·7h ago
More News
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Zacks·9h ago
Reynders McVeigh Capital Management LLC Acquires New Shares in Novo Nordisk A/S $NVO
Reynders McVeigh Capital Management LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 2nd quarter, according to its most recent filing with the Securities...
MarketBeat·10h ago
2 Predictions for Novo Nordisk in 2026
Key PointsNovo Nordisk has the potential to maintain more consistent revenue growth throughout next year...
Nasdaq News: Markets·1d ago
Novo Nordisk A/S $NVO Shares Purchased by Saratoga Research & Investment Management
Saratoga Research & Investment Management boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 4.0% during the second quarter, according to the company in its most recent...
MarketBeat·1d ago
Marex Group plc Buys New Stake in Novo Nordisk A/S $NVO
Marex Group plc purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat·1d ago
28,655 Shares in Novo Nordisk A/S $NVO Purchased by Coppell Advisory Solutions LLC
Coppell Advisory Solutions LLC purchased a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The firm purchased...
MarketBeat·2d ago
European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy
EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in the U.S., U.K., and other markets.read more...
Benzinga·3d ago
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win
LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.
Zacks·3d ago
NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.